Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adagio Medical Holdings (ADGM) Cash & Equivalents (2023 - 2026)

Adagio Medical Holdings has reported Cash & Equivalents over the past 4 years, most recently at $12.9 million for Q1 2026.

  • Quarterly Cash & Equivalents changed 0.42% to $12.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $12.9 million through Mar 2026, changed 0.42% year-over-year, with the annual reading at $17.1 million for FY2025, 16.97% down from the prior year.
  • Cash & Equivalents was $12.9 million for Q1 2026 at Adagio Medical Holdings, down from $17.1 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $28.3 million in Q3 2024 and troughed at $1.4 million in Q4 2023.
  • The 4-year median for Cash & Equivalents is $12.9 million (2025), against an average of $13.3 million.
  • Year-over-year, Cash & Equivalents soared 1389.52% in 2024 and then crashed 83.39% in 2025.
  • A 4-year view of Cash & Equivalents shows it stood at $1.4 million in 2023, then soared by 1389.52% to $20.6 million in 2024, then dropped by 16.97% to $17.1 million in 2025, then dropped by 24.53% to $12.9 million in 2026.
  • Per Business Quant, the three most recent readings for ADGM's Cash & Equivalents are $12.9 million (Q1 2026), $17.1 million (Q4 2025), and $4.7 million (Q3 2025).